Urolog. pro Praxi, 2006; 6: 278-282

Botulinum toxin - structure, mechanism of action and current clinical applications

MUDr. Jan Krhut
Urologické oddělení FNsP Ostrava

Botulinum toxin (BTX) is the most poisonous substance known. Currently, though, it is drawing attention of health care professionals and is being used in a number of clinical applications. Most commonly, it is used to treat muscular spasticities, hyperhidrosis, focal dysphonias, blepharospasms, overactive bladder, pelvic pain syndrome, tension cephalalgia, migraine, achalasia, anal fissures, or vaginismus. The number of indications to use botulinum toxin is steadily increasing, thus it is sometimes referred to as the penicillin of the 21st century.

The paper presents an overview of the structure, mechanisms of action and clinical applications of this substance.

Keywords: Key words: botulinum toxin, clostridium, neuromuscular junction, neurotoxin, acetylcholine.

Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krhut J. Botulinum toxin - structure, mechanism of action and current clinical applications. Urol. praxi. 2006;7(6):278-282.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aoki KR. Pharmacology and imunology of botulinum toxin type A serotypes. Clin Dermatos 2003; 21: 476-480. Go to original source... Go to PubMed...
    2. Bennett MK, Calakos N, Schiller RH. Syntaxin: a synaptic protein implicated in docking of synaptic vesicles at presynaptic active zones. Science 1992; 257: 255-259. Go to original source... Go to PubMed...
    3. Brin MF, Fahn S, Moskowitz S, Friedmann A, Shale HM, Greene PE, List T, Lange D, Lovace RE. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987; 2: 237-254. Go to original source... Go to PubMed...
    4. Brin MF, Vapnek JM: Treatment of vaginismus with botulinum toxin injections. Lancet 1997; 349: 252-253. Go to original source... Go to PubMed...
    5. Burgen A, Dickens F Zatman LJ. The action of botulinum toxin on the neuromuscular junction. J Physiol 1949; 109: 10-24. Go to original source... Go to PubMed...
    6. Burningham MD, Walter FG, Mechem C, Haber J, Ekins BR: Wound botulism. Ann Emerg Med 1994; 24: 1184-1187. Go to original source... Go to PubMed...
    7. Bushara KO, Park DM, Jones JC, Schutta HS: Botulinum toxin: a possible new treatment for axillary hyperhydrosis. Clin Exp Derm 1996; 21: 276-278. Go to original source... Go to PubMed...
    8. Carl S, Forth H, Breul J: Botulinum -A-Toxin (Dysport) zur Behandlung von Patienten mit interstitieller Cystitis. Urologe A 2003; 42 (Suppl. 1): 49.
    9. Doggweiller R, Hermann DH, Ishigooka M, Schmidt RA: Botox-induced prostatic involution. The Prostate 1998; 37: 44-50. Go to original source... Go to PubMed...
    10. Dressler D, Benecke R. Perspektiven der Botulinumtoxintherapie der Dystonie. Klin Neuroneurophysiol 2001; 32: 213-217. Go to original source...
    11. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988; 139: 919-922. Go to original source... Go to PubMed...
    12. Eisenbart GS, Oie H, Gazdar A, Chick W, Schultz JA, Scearce RM: Production of monoclonal antibodies reacting with rat islet cell membrane antigens. Diabetes 1981; 30: 226-230. Go to original source... Go to PubMed...
    13. Erdal E, Bartels F, Binscheck T, Erdmann G, Frevert J, Kistner A, Keller U, Wever J, Bigalke H. Processing of tetanus and botulinum A neurotoxins in isolated chromaffin cells. Naunyn Schmiedeberg´s Arch Pharmacol 1995; 351: 67-78. Go to original source... Go to PubMed...
    14. Fahn S, List T, Moskowitz CB, Brin MF, Bresmann S, Burke R, Scott AB. Double-blindcontrolled study of botulinum toxin for blepharospasm. Neurology 1985; 25 (Suppl): 271. Go to PubMed...
    15. Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms and rigidity. Neurology 1995; 45: 712-717. Go to original source... Go to PubMed...
    16. Greene P, Fahn S, Diamond B. Development of resistence to botulinumtoxin type A in pastients with torticollis. Mov Disord 1994; 9: 213-217. Go to original source... Go to PubMed...
    17. Jost WH: Treatment of detrusor-sphincter dyssynergia with botulinum toxin. J Neurol 1999; 246: 89.
    18. Kerner JC. Vergiftung durch verdorbene Würste. Tübinger Blätter für Naturwissenschaften und Arzneykunde 1817; 3: 1-45.
    19. Maria G, Cassetta E, Gui D, Brisinda G, Bentivoglio AR, Albanese A: A comparsion of botulinum toxin and saline for the treatment of chronic anal fissure. N Engl. J Med 1998; 338: 217-220. Go to original source... Go to PubMed...
    20. Montecucco C, Papini E, Schiavo G. Bacterial protein toxins and cell vesicle trafficking. Experientia 1996; 52: 1026-1032). Go to original source... Go to PubMed...
    21. Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, Marttila RJ, Lundh H, Gedin S, Westergren I, Richardson A, Dott C, Cohen H. A double blind, randomised, paralel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998; 64: 6-12. Go to original source... Go to PubMed...
    22. Pastucha PJ, Ravich WJ, Hendrix TR, Sostre S, Jones B, Kalloo AN: Intrashpincteric botulinum toxin for the treatment of achalasia. N Engl J Med 1995; 332: 774-778. Go to original source... Go to PubMed...
    23. Phelan MW, Franks M, Somogyi GT. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 2001; 165/4: 1107-1110. Go to original source... Go to PubMed...
    24. Radziszewski P, Borkowski A. Botulinum toxin type A intravesical injections for instable bladder overactivity. Eur Urol 2002; (Suppl. 1): 134. Go to original source...
    25. Reitz A, von Tobel J, Stöhrer M. European experience of 184 cases treated with botulinum - a toxin injections into detrusor muscle for neurogenic incontinence. Neurourol Urodyn 2002; 21: 427-428.
    26. Rollnik JD, Tanneberger O, Schubert M, Schneider U, Dengler R: Treatment of pension-type headache with botulinum toxin type A: a double-blind placebo-controlled study. Headache 2000; 40: 300-305. Go to original source... Go to PubMed...
    27. Scott AB. Botulinum toxin injection of eye muscles to correct stabismus. Trans Am Ophalmol Soc 1981; 79: 734-770.
    28. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 1988; 3: 333-335. Go to original source... Go to PubMed...
    29. Schurch B, Stöhrer M, Kramer G, Schmid D, Gaul G, Hauri D. Botulinum - a-toxin for treating detrusor hyperreflexia in spinal cord injured patiens: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164: 692-697. Go to original source... Go to PubMed...
    30. Silberstein S, Matjes N, Saper J, Jenkins S. Botulinum toxin type A as migraine preventive treatment. Headache 2000; 40: 445-450. Go to original source... Go to PubMed...
    31. Williamson LC, Halpern JL, Montecucco C, Brown JE, Neale EA: Clostridial neurotoxins and substrate proteolysis in intact neurons: botulinum neurotoxin C acts on synaptosomal-associated protein of 25 kDa. J Biol Chem 1996; 271: 7694-7699. Go to original source... Go to PubMed...
    32. Zermann DH, Ishigooka M, Doggweiler-Wiygul R, Schubert J, Schmidt RA: The male chronic pelvic pain syndrome. World J Urol 2001; 19/3: 173-179. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.